 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 851726
Online Users : 1023
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/1232
|
| Title: | Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[3-hydroxyadamantan-1-yl) amino]acetyl}-pyrrolidine-2-carbonitrile) |
| Authors: | Brandt, I;Joossens, J;Chen, X;Maes, MB;Scharpe, S;De Meester, I;Lambeir, AM |
| Contributors: | Division of Biotechnology and Pharmaceutical Research |
| Abstract: | Vildagliptin (NVP-LAF237/(2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl)}-pyrrolidine-2-carbonitrile) was described as a potent, selective and orally bio-available dipeptidyl-peptidase IV (DPP IV, EC 3.4.14.5) inhibitor [Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, et al. 1-[[(3-Hydroxy-1-adamantyl)amino] acetyl] - 2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774-89]. Phase III clinical trials for the use of this compound in the treatment of Type 2 diabetes were started in the first quarter of 2004. In this paper, we report on (1) the kinetics of binding, (2) the type of inhibition, (3) the selectivity with respect to other peptidases, and (4) the inhibitory potency on the DPP IV catalyzed degradation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and substance P. Vildagliptin behaved as a slow-binding DPP IV inhibitor with an association rate constant of 1.4 x 10(5) M-1 s(-1) and a K-i of 17 nM. It is a micromolar inhibitor for dipeptidyl-peptidase 8 and does not significantly inhibit dipeptidyl-peptidase II (EC 3.4.11.2), prolyl oligopeptidase (EC 3.4.21.26), aminopeptidase P (EC 3.4.11.9) or aminopeptidase M (EC 3.4.11.2). There was no evidence for substrate specific inhibition of DPP IV by Vildagliptin or for important allosteric factors affecting the inhibition constant in presence of GIP and GLP-1. (c) 2005 Elsevier Inc. All rights reserved. |
| Keywords: | Pharmacology & Pharmacy |
| Date: | 2005-07-01 |
| Relation: | Biochemical Pharmacology. 2005 Jul;70(1):134-143. |
| Link to: | http://dx.doi.org/10.1016/j.bcp.2005.04.009 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0006-2952&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000229979500014 |
| Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=20444406121 |
| Appears in Collections: | [陳新(2002-2015)] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| 000229979500014.pdf | | 342Kb | Adobe PDF | 588 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
